Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

Status:	Completed
Conditions:	Lymphoma, Lymphoma
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - 99
Updated:	12/19/2018
Start Date:	August 2003
End Date:	December 2010

A Phase 1 Study Of Cmc-544 Administered As A Single Agent In Subjects With B-cell Non- Hodgkin's Lymphoma

To determine the Maximum Tolerated Dose (MTD), the tolerability, and the initial safety
profile of CMC-544 in subjects with B-cell Non-Hodgkin's Lymphoma (NHL).

Inclusion Criteria:

- Subjects who have been previously diagnosed with CD22-positive, B-cell NHL, according
to WHO classification, which has progressed after at least 2 prior therapies of
probable clinical benefit

- At the expanded cohort, part 2 of the study, subjects must have one of the following:

- Follicular lymphoma previously treated with at least one dose of rituximab, but have
not received radioimmunotherapy

- Diffuse large B-cell lymphoma

- Age 18 years or older

Exclusion Criteria:

- Candidate for potentially curative therapies in the opinion of the investigator

- Chronic lymphocytic leukemia

- Burkitt's lymphoma, primary effusion lymphoma, and precursor B-cell lymphoblastic
lymphoma

We found this trial at

sites

Roswell Park Cancer Institute

666 Elm Street
Buffalo, New York 14263

(716) 845-2300